We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Antibody Test Predicts Cold-Related Asthma Attacks

By LabMedica International staff writers
Posted on 17 Dec 2014
Print article
Image: The MRX Microplate Reader for enzyme-linked immunosorbent assays (Photo courtesy of Dynatech Laboratories).
Image: The MRX Microplate Reader for enzyme-linked immunosorbent assays (Photo courtesy of Dynatech Laboratories).
Image: The ImmunoCAP 250 analyzer for allergy and autoimmunity testing (Photo courtesy of Phadia).
Image: The ImmunoCAP 250 analyzer for allergy and autoimmunity testing (Photo courtesy of Phadia).
A diagnostic marker can be used to identify the risk group for asthma attacks caused by rhinoviruses and this can be assessed with a simple antibody test.

Rhinoviruses (RVs) are the most common cause of respiratory illnesses in children and adults of all ages and are responsible for more than half of all acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Immunologists at the Medical University of Vienna (Austria) working with their colleagues in the UK studied the response to infections with RV16 that were induced in 28 asthmatic patients (11 with mild asthma and 17 with moderate asthma and 11 healthy adult individuals. The healthy adult subjects were non-smoking, non-atopic and non-asthmatic volunteers aged 21 to 55 years. Patients with mild asthma were aged 19 to 53 years taking only short-acting β2 agonists (SABA). The patients with moderate asthma, aged 20–54 years were on SABA) plus inhaled corticosteroid therapy.

Total immunoglobulin E (IgE) levels were measured using ImmunoCAP technology (Phadia; Uppsala, Sweden); healthy median: was 16 IU/mL; mild asthmatics median: was 207 IU/mL; and moderate asthmatics median was 132 IU/mL. Enzyme-linked immunosorbent assays (ELISA) were performed with expressed and purified recombinant RV coat proteins VP1-4, nonstructural proteins as well as N-terminal fragments of VP1 from four RV strains (RV14, 16, 89, C) covering the three known RV groups (RV-A, RV-B and RV-C) and measured specific IgG-subclass-, IgA- and IgM-responses in subjects with different severities of asthma or without asthma before and after experimental infection with RV16. The optical density (OD) values corresponding to the levels of antigen-specific antibodies were measured at 405 and 490 nm in an ELISA reader (Dynatech; Denkendorf, Germany).

The results of the subsequent antibody tests using recombinant virus antigens that were developed showed that the asthmatics who experienced attacks expressed significantly higher antibodies to the structure protein VP1, which is found in all of the known 150 or so rhinovirus strains, than any of the other subjects. The raised antibody response to VP1 now allows all individuals who need particular protection against colds to be identified.

The authors concluded that ultimately serological tests may be helpful for identifying the most common and clinically relevant rhinovirus strains involved in asthma exacerbations and to investigate in cross-sectional studies the possible role of rhinovirus infections in other respiratory diseases, in different geographic populations and age groups including not only children but also adults and elderly persons. The study was published on November 18, 2014, in the journal EbioMedicine.

Related Links:

Medical University of Vienna
Phadia 
Dynatech 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.